In this article, evidence is reviewed suggesting that the outcome of cancer immunotherapy depends on pre-treatment immune parameters of a patient. The results described in the article show that immunotherapy may prolong survival in certain subgroups of cancer patients, while in other subgroups a cancer-promoting effect of this treatment modality cannot be excluded.
Cancer immunotherapy is a rapidly expanding area of research and clinical practice. Cytokines, monoclonal antibodies, vaccines and adoptive cell immunotherapy are increasingly being studied in trials and used in clinics. There is one aspect, however, which has been largely ignored in cancer immunotherapy studies: heterogeneity of survival rates among untreated patients. If this is taken into account, two questions remain to be answered. First, what is the role of immunological factors in determining the survival of untreated cancer patients? Second, do patients with good immunological prognostic factors benefit from immunotherapy?
Regarding the clinical outcome, renal cell carcinoma (RCC) is one of the most heterogeneous of adult malignancies. In general, outcome of patients with metastatic RCC is poor with the median survival of approximately 1 y. However, some primary tumors and metastases of RCC, especially pulmonary parenchymal lesions, may have periods with little or no growth during many months. 1 A subset (from 10% to 20%) of patients with metastatic RCC survive 5 or more years. 1, 2 In the late nineties, our group has studied the prognostic significance of peripheral blood lymphocyte subsets in advanced RCC patients using flow cytometry. We found remarkable differences in overall survival of advanced RCC patients based on peripheral blood levels of CD8 high CD57 + lymphocytes. 3 In our analysis, the median overall survival of patients with , 30% CD8 high CD57 + lymphocytes in the CD8 + subset was 23.5 mo (the "relatively good prognosis group"), whereas the median overall survival of patients with $ 30% CD8 high CD57
+ lymphocytes in the CD8 + subset was only 6 mo (the "bad prognosis group"). High expression of CD8 antigen distinguishes CD8 + T cells from CD8 + NK cells that have low expression of CD8. 4 Expression of CD57 antigen on T lymphocytes is regarded as a marker of immune deficiency in patients with autoimmune disease, infectious diseases and cancer. 5 Thus, differences in survival among untreated advanced RCC patients may depend on immunological factors, i.e., levels of CD8 high CD57 + lymphocytes. During 1995-1999, interferon-a (IFNa) was just being introduced in Lithuania, and no strict guidelines toward its use for treatment of metastatic RCC were available. Due to considerable variability in approach to treatment of metastatic RCC patients in Lithuania, we were able to select subgroups of patients treated and non-treated with IFNa. Thus, we had the opportunity to perform a retrospective analysis of the predictive significance of peripheral blood lymphocyte subsets for treatment with IFNa of patients with advanced RCC. Treatment with IFNa significantly increased the median overall survival of the "bad prognosis group" RCC patients (from 6 to 18.5 mo). In contrast, a trend toward decreased median overall survival was observed in the "relatively good prognosis group" after treatment with IFNa (13.6 mo of IFNatreated patients vs. 23.5 mo of patients non-treated with IFNa). 3 These our results suggest, that immunotherapy with IFNa may benefit patients with poor immunological prognostic factors, whereas this treatment may even be harmful for patients with good immunological prognostic factors.
Thousands of melanoma patients have been enrolled in adjuvant IFNa trials with the aim to determine a statistically significant improvement in survival. In a recent systematic review and meta-analysis of 14 randomized controlled trials including a total of 8,122 patients, it was shown that treatment with IFNa statistically significantly improves the overall survival of high-risk melanoma patients with a risk reduction of 11%. 6 However, it has to be taken into account that 60% of patients + lymphocytes in the CD8 + subset was not reached at a median follow-up of 24.6 mo, whereas median overall survival of patients with . 23% CD8 high CD57
+ lymphocytes was only 14.2 mo. 8 The detrimental effect of adjuvant IFNa in the latter group of patients cannot be excluded.
In conclusion, our results reviewed in this article and the results by other authors (for a review see ref. 9 ) strongly suggest that the outcome of immunotherapy depends on pre-treatment immune parameters of a cancer patient. Immunotherapy may prolong survival in certain subgroups of patients, most likely in those with poor immunological prognostic factors. However, immunotherapy should be administered cautiously to patients with good immunological prognostic factors, because a cancer-promoting effect of this treatment modality cannot be excluded (for a review see ref. 7) . Schematic outline of the implications of the data reviewed in this article is shown in Figure 1 . CD8 + T lymphocytes are welldocumented effectors of tumor immunity. There is ample evidence on the prognostic significance of CD8 + lymphocytes within a tumor or in peripheral blood of cancer patients. 9, 10 Thus, numbers and maybe functional characteristics of CD8 + T lymphocytes or their subsets may reflect the immunologic reactivity of the cancer patient and predict beneficial or harmful effects of immunotherapy. Our results support the predictive significance of peripheral blood CD8 high CD57 + lymphocyte levels, but more research is needed. Figure 1 . Schematic outline of the implications of the data reviewed in this article. Depending on pre-treatment immune parameters, immunotherapy may prolong survival in one subgroup of patients, while in another subgroup survival may be decreased compared with non-treated patients. As a result, the total effect of the therapeutic intervention may be nullified.
